Such conversations are becoming increasingly common as demand for weight-loss drugs explodes in urban India - a country with ...

Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...

Eli Lilly chairman and CEO David Ricks joins CNBC’s “Squawk on the Street” team to discuss its quarterly earnings report that ...

Eli Lilly reported higher profit and raised its outlook on surging demand for its weight-loss drugs, sending its shares ...

Eli Lilly raised its full-year profit and revenue forecasts on Thursday as strong overseas demand for weight-loss and ...

Until recently, GLP -1s, a powerful new class of weight-loss drugs, were confined mostly to rich countries. Yet the World ...

Merck, which has claimed bragging rights as the maker of the world’s best-selling drug, Keytruda, since 2023, has officially ...

Eli Lilly hiked its outlook as sales soared for its popular weight-loss drugs Zepbound and Mounjaro.  The company also ...

Mounjaro generated sales of $6.5bn in Q3 2025, up 109% from the same period in 2024. Zepbound exhibited even higher growth – ...

Eli Lilly beat Q3 estimates with $7.02 EPS and $17.60 billion revenue, raising full-year guidance as Zepbound and Mounjaro ...

Eli Lilly's experimental weight-loss pill, orforglipron, has met key FDA criteria for an expedited review, boosting its ...